12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivantinib: Phase III discontinued

ArQule and Daiichi Sankyo discontinued the double-blind, international Phase III MARQUEE trial in about 1,000 NSCLC patients after a planned interim analysis by an independent DMC showed that twice-daily 360 mg oral tivantinib plus Tarceva erlotinib would miss the primary endpoint of OS vs. placebo plus Tarceva. The partners did say that tivantinib plus Tarceva significantly improved PFS, a secondary endpoint, vs. placebo plus Tarceva. No safety concerns were identified. The trial enrolled patients with locally advanced or metastatic, non-squamous NSCLC who...

Read the full 398 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >